Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
RIGL's Cash to Debt is ranked higher than
85% of the 1158 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. RIGL: No Debt )
RIGL' s 10-Year Cash to Debt Range
Min: 0.76   Max: No Debt
Current: No Debt

Equity to Asset 0.83
RIGL's Equity to Asset is ranked higher than
90% of the 965 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. RIGL: 0.83 )
RIGL' s 10-Year Equity to Asset Range
Min: 0.04   Max: 0.93
Current: 0.83

0.04
0.93
Interest Coverage No Debt
RIGL's Interest Coverage is ranked higher than
72% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 236.52 vs. RIGL: No Debt )
RIGL' s 10-Year Interest Coverage Range
Min: 388.1   Max: 9999.99
Current: No Debt

388.1
9999.99
F-Score: 3
Z-Score: -0.90
M-Score: -3.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1106.05
RIGL's Operating margin (%) is ranked lower than
56% of the 1107 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.08 vs. RIGL: -1106.05 )
RIGL' s 10-Year Operating margin (%) Range
Min: -14938.27   Max: 28.25
Current: -1106.05

-14938.27
28.25
Net-margin (%) -1101.92
RIGL's Net-margin (%) is ranked lower than
56% of the 1107 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.46 vs. RIGL: -1101.92 )
RIGL' s 10-Year Net-margin (%) Range
Min: -14872.93   Max: 30.31
Current: -1101.92

-14872.93
30.31
ROE (%) -54.28
RIGL's ROE (%) is ranked lower than
51% of the 1135 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.08 vs. RIGL: -54.28 )
RIGL' s 10-Year ROE (%) Range
Min: -142.04   Max: 27.46
Current: -54.28

-142.04
27.46
ROA (%) -48.92
RIGL's ROA (%) is ranked lower than
53% of the 1169 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.54 vs. RIGL: -48.92 )
RIGL' s 10-Year ROA (%) Range
Min: -101.94   Max: 23.14
Current: -48.92

-101.94
23.14
ROC (Joel Greenblatt) (%) -2647.35
RIGL's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 1164 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.30 vs. RIGL: -2647.35 )
RIGL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4462.67   Max: 1034.93
Current: -2647.35

-4462.67
1034.93
Revenue Growth (3Y)(%) 4.00
RIGL's Revenue Growth (3Y)(%) is ranked higher than
68% of the 948 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. RIGL: 4.00 )
RIGL' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 75.5
Current: 4

0
75.5
EBITDA Growth (3Y)(%) -8.80
RIGL's EBITDA Growth (3Y)(%) is ranked higher than
62% of the 846 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. RIGL: -8.80 )
RIGL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -47.1   Max: 23.2
Current: -8.8

-47.1
23.2
EPS Growth (3Y)(%) -8.60
RIGL's EPS Growth (3Y)(%) is ranked higher than
65% of the 822 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. RIGL: -8.60 )
RIGL' s 10-Year EPS Growth (3Y)(%) Range
Min: -56.5   Max: 21.8
Current: -8.6

-56.5
21.8
» RIGL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

RIGL Guru Trades in Q1 2014

Charles Brandes 15,000 sh (New)
Paul Tudor Jones 11,687 sh (New)
Steven Cohen 27,339 sh (+26.57%)
Chuck Royce 309,392 sh (+0.13%)
Jim Simons 210,526 sh (-81.70%)
» More
Q2 2014

RIGL Guru Trades in Q2 2014

Jim Simons 421,254 sh (+100.10%)
Paul Tudor Jones 11,950 sh (+2.25%)
Charles Brandes 15,000 sh (unchged)
Chuck Royce 215,392 sh (-30.38%)
» More
Q3 2014

RIGL Guru Trades in Q3 2014

Jim Simons 589,326 sh (+39.90%)
Chuck Royce 215,392 sh (unchged)
Charles Brandes Sold Out
Paul Tudor Jones Sold Out
» More
Q4 2014

RIGL Guru Trades in Q4 2014

Chuck Royce 215,392 sh (unchged)
Jim Simons 516,726 sh (-12.32%)
» More
» Details

Insider Trades

Latest Guru Trades with RIGL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.10
RIGL's P/B is ranked higher than
75% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.20 vs. RIGL: 3.10 )
RIGL' s 10-Year P/B Range
Min: 1.02   Max: 15.5
Current: 3.1

1.02
15.5
P/S 51.80
RIGL's P/S is ranked lower than
62% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.25 vs. RIGL: 51.80 )
RIGL' s 10-Year P/S Range
Min: 2.8   Max: 979
Current: 51.8

2.8
979
Current Ratio 10.73
RIGL's Current Ratio is ranked higher than
95% of the 1028 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.23 vs. RIGL: 10.73 )
RIGL' s 10-Year Current Ratio Range
Min: 0.9   Max: 24.78
Current: 10.73

0.9
24.78
Quick Ratio 10.73
RIGL's Quick Ratio is ranked higher than
96% of the 1028 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. RIGL: 10.73 )
RIGL' s 10-Year Quick Ratio Range
Min: 0.9   Max: 24.78
Current: 10.73

0.9
24.78
Days Sales Outstanding 254.39
RIGL's Days Sales Outstanding is ranked higher than
57% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 89.68 vs. RIGL: 254.39 )
RIGL' s 10-Year Days Sales Outstanding Range
Min: 12.04   Max: 293.53
Current: 254.39

12.04
293.53

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.70
RIGL's Price/Net Cash is ranked higher than
97% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. RIGL: 3.70 )
RIGL' s 10-Year Price/Net Cash Range
Min: 1.28   Max: 10.98
Current: 3.7

1.28
10.98
Price/Net Current Asset Value 3.50
RIGL's Price/Net Current Asset Value is ranked higher than
97% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. RIGL: 3.50 )
RIGL' s 10-Year Price/Net Current Asset Value Range
Min: 1.23   Max: 10.16
Current: 3.5

1.23
10.16
Price/Tangible Book 3.30
RIGL's Price/Tangible Book is ranked higher than
81% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. RIGL: 3.30 )
RIGL' s 10-Year Price/Tangible Book Range
Min: 1.02   Max: 14.13
Current: 3.3

1.02
14.13
Price/Median PS Value 1.40
RIGL's Price/Median PS Value is ranked higher than
80% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. RIGL: 1.40 )
RIGL' s 10-Year Price/Median PS Value Range
Min: 0.07   Max: 24.38
Current: 1.4

0.07
24.38
Earnings Yield (Greenblatt) -34.70
RIGL's Earnings Yield (Greenblatt) is ranked lower than
62% of the 1156 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. RIGL: -34.70 )
RIGL' s 10-Year Earnings Yield (Greenblatt) Range
Min: -40.8   Max: 6128.3
Current: -34.7

-40.8
6128.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:RI2A.Germany,
Rigel Pharmaceuticals Inc was incorporated in the state of Delaware on June 14, 1996. The Company is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. The Companys pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The Company currently has five product candidates in development: fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor entering in Phase 3 clinical trials for immune thrombocytopenic purpura (ITP) and a Phase 2 clinical trial for immunoglobulin A nephropathy (IgAN) in the first half of 2014; R348, a topical JAK/SYK inhibitor currently in Phase 2 clinical trials for dry eye; R118, an adenosine monophosphate (AMP)-activated protein kinase (AMPK) activator entering Phase 1 in the first half of 2014; and two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo, respectively. The Company is conducting proprietary research in the broad disease areas of inflammation/immunology and muscle wasting/muscle endurance. The Companys major competitors include fully integrated pharmaceutical companies that have extensive drug discovery efforts and are developing novel small molecule pharmaceuticals. The Company is subject to extensive regulation by numerous governmental authorities in the United States and other countries, including the FDA under the Federal Food, Drug and Cosmetic Act.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK